Nanoviricides (NV) has announced its first clinical study, a key milestone in The development of its novel and innovative anti-virus therapy, NV-CoV-2.
Poolbeg Pharma has disclosed selected data from its human volunteer LPS challenge trial (EudraCT N0: 2022-001458-48) with its lead molecule POLB 001, following its initial announcement of the study's success in January.
Poolbeg Pharma has disclosed selected data from its human volunteer LPS challenge trial (EudraCT N0: 2022-001458-48) with its lead molecule POLB 001, following its initial announcement of the study's success in January.
Poolbeg Pharma has disclosed selected data from its human volunteer LPS challenge trial (EudraCT N0: 2022-001458-48) with its lead molecule POLB 001, following its initial announcement of the study's success in January.
Poolbeg Pharma has disclosed selected data from its human volunteer LPS challenge trial (EudraCT N0: 2022-001458-48) with its lead molecule POLB 001, following its initial announcement of the study's success in January.
Poolbeg Pharma has disclosed selected data from its human volunteer LPS challenge trial (EudraCT N0: 2022-001458-48) with its lead molecule POLB 001, following its initial announcement of the study's success in January.
Poolbeg Pharma has disclosed selected data from its human volunteer LPS challenge trial (EudraCT N0: 2022-001458-48) with its lead molecule POLB 001, following its initial announcement of the study's success in January.